Ken Griffin Myriad Genetics Inc Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 24,900 shares of MYGN stock, worth $150,147. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,900

Previous 15,400 61.69%

Holding current value

$150,147

Previous $136,000 2.94%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.84 - $8.84 $4.52 Million - $10.4 Million	1,175,890 Added 219.74%	1,711,021 $9.09 Million
Q1 2025 May 15, 2025	SELL	$8.87 - $14.98 $2.04 Million - $3.45 Million	-230,110 Reduced 30.07%	535,131 $4.75 Million
Q4 2024 Feb 14, 2025	BUY	$13.17 - $27.03 $9.18 Million - $18.8 Million	697,180 Added 1024.35%	765,241 $10.5 Million
Q3 2024 Nov 14, 2024	SELL	$23.97 - $28.6 $40.7 Million - $48.5 Million	-1,695,989 Reduced 96.14%	68,061 $1.86 Million
Q2 2024 Aug 14, 2024	BUY	$17.98 - $25.47 $7.15 Million - $10.1 Million	397,503 Added 29.09%	1,764,050 $43.1 Million
Q1 2024 May 15, 2024	BUY	$17.59 - $23.59 $3.56 Million - $4.78 Million	202,465 Added 17.39%	1,366,547 $29.1 Million
Q4 2023 Feb 14, 2024	BUY	$13.91 - $21.32 $6.83 Million - $10.5 Million	490,838 Added 72.91%	1,164,082 $22.3 Million
Q3 2023 Nov 14, 2023	BUY	$15.99 - $23.22 $10.2 Million - $14.8 Million	635,471 Added 1682.34%	673,244 $10.8 Million
Q2 2023 Aug 14, 2023	BUY	$17.56 - $23.76 $625,627 - $846,521	35,628 Added 1660.98%	37,773 $875,000
Q1 2023 May 15, 2023	SELL	$15.26 - $23.75 $473,853 - $737,485	-31,052 Reduced 93.54%	2,145 $49,000
Q4 2022 Feb 14, 2023	BUY	$14.51 - $20.99 $481,688 - $696,805	33,197 New	33,197 $481,000
Q1 2022 May 16, 2022	SELL	$22.67 - $28.01 $244,881 - $302,564	-10,802 Reduced 20.07%	43,022 $1.08 Million
Q4 2021 Feb 14, 2022	SELL	$24.13 - $32.63 $478,497 - $647,052	-19,830 Reduced 26.92%	53,824 $1.49 Million
Q3 2021 Nov 15, 2021	SELL	$29.97 - $36.66 $2.23 Million - $2.72 Million	-74,262 Reduced 50.21%	73,654 $2.38 Million
Q2 2021 Aug 16, 2021	SELL	$25.39 - $32.61 $265,528 - $341,035	-10,458 Reduced 6.6%	147,916 $4.52 Million
Q1 2021 May 17, 2021	BUY	$19.92 - $31.6 $2.51 Million - $3.99 Million	126,116 Added 390.96%	158,374 $4.82 Million
Q4 2020 Feb 16, 2021	SELL	$12.16 - $19.77 $67,767 - $110,178	-5,573 Reduced 14.73%	32,258 $638,000
Q3 2020 Nov 16, 2020	BUY	$11.25 - $14.75 $47,711 - $62,554	4,241 Added 12.63%	37,831 $493,000
Q2 2020 Aug 14, 2020	SELL	$10.69 - $16.49 $488,832 - $754,054	-45,728 Reduced 57.65%	33,590 $381,000
Q1 2020 May 15, 2020	BUY	$9.78 - $29.53 $447,376 - $1.35 Million	45,744 Added 136.25%	79,318 $1.14 Million
Q3 2019 Nov 14, 2019	SELL	$22.08 - $47.08 $3.19 Million - $6.8 Million	-144,517 Reduced 81.15%	33,574 $961,000
Q2 2019 Aug 14, 2019	SELL	$22.67 - $35.0 $1.32 Million - $2.04 Million	-58,158 Reduced 24.62%	178,091 $4.95 Million
Q1 2019 May 15, 2019	SELL	$26.93 - $34.7 $1.79 Million - $2.31 Million	-66,541 Reduced 21.98%	236,249 $0
Q4 2018 Feb 14, 2019	BUY	$27.23 - $45.56 $2.29 Million - $3.83 Million	84,024 Added 38.41%	302,790 $8.8 Million
Q3 2018 Nov 13, 2018	BUY	$37.57 - $50.34 $5.16 Million - $6.91 Million	137,291 Added 168.51%	218,766 $0
Q2 2018 Aug 10, 2018	BUY	$27.75 - $40.17 $1.57 Million - $2.28 Million	56,639 Added 228.05%	81,475 $0
Q1 2018 May 11, 2018	SELL	$28.83 - $41.01 $829,669 - $1.18 Million	-28,778 Reduced 53.68%	24,836 $734,000
Q4 2017 Feb 09, 2018	BUY	$28.45 - $37.14 $1.11 Million - $1.44 Million	38,902 Added 264.42%	53,614 $1.84 Million
Q3 2017 Nov 09, 2017	BUY	$24.01 - $36.2 $353,235 - $532,574	14,712	14,712 $532,000

Others Institutions Holding MYGN

# of Institutions

232

Shares Held

94.1M

Call Options Held

450K

Put Options Held

14.2K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $486M
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account